Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

The OVAL study for VB-111 treatment of platinum-resistant ovarian cancer

Objetivo

VBL therapeutics is a late-stage clinical biopharmaceutical company focused on first in class treatments for cancer. VBL's lead oncology product candidate, VB-111, is an innovative targeted anti-cancer gene therapy with potential to treat a wide range of solid tumors. Most cancer therapies aim to target tumors cells while sparing normal cells, but tumors are heterogeneous and often develop resistance to treatment. Instead of targeting the tumor directly, VB-111 targets the tumor environment by disrupting the blood vessels that supply blood to the tumor and by recruiting the immune system into the tumor. This dual mechanism of action together with an excellent safety profile make VB-111 a game-changer. VBL is pursuing Ovarian Cancer as the first indication for VB-111. In the scope of this project, VBL will to finalize a Phase 3 potential-registration clinical trial, the OVAL study as well as execute all the necessary steps towards final regulatory approvals and commercialization

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) HORIZON-EIC-2021-ACCELERATOROPEN-01

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

VASCULAR BIOGENICS LTD
Aportación neta de la UEn
€ 2 500 000,00
Dirección
8 HASATAT STREET
7178106 MODIIN
Israel
Pyme
Sí
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 7 037 500,00